Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) was the recipient of some unusual options trading activity on Tuesday. Investors bought 5,753 call options on the company. This represents an increase of approximately 1,019% compared to the average daily volume of 514 call options.

A number of analysts have recently issued reports on MDGL shares. Oppenheimer cut their target price on shares of Madrigal Pharmaceuticals from $300.00 to $200.00 and set an “outperform” rating for the company in a research note on Monday. Raymond James cut shares of Madrigal Pharmaceuticals from a “market perform” rating to an “underperform” rating in a research note on Monday. BidaskClub cut shares of Madrigal Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday. Evercore ISI upgraded shares of Madrigal Pharmaceuticals from an “in-line” rating to an “outperform” rating and raised their target price for the stock from $222.00 to $250.00 in a research note on Friday, November 16th. Finally, Cowen restated a “buy” rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, November 7th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $297.63.

In other news, CEO Paul A. Friedman purchased 4,000 shares of the business’s stock in a transaction on Monday, November 19th. The stock was purchased at an average price of $124.00 per share, for a total transaction of $496,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Fred B. Craves purchased 2,000 shares of the business’s stock in a transaction on Monday, November 19th. The stock was purchased at an average price of $124.69 per share, with a total value of $249,380.00. The disclosure for this purchase can be found here. Company insiders own 56.70% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Legal & General Group Plc increased its position in Madrigal Pharmaceuticals by 166.0% during the third quarter. Legal & General Group Plc now owns 2,535 shares of the biopharmaceutical company’s stock worth $542,000 after acquiring an additional 1,582 shares during the period. TIAA CREF Investment Management LLC increased its position in Madrigal Pharmaceuticals by 3.4% during the third quarter. TIAA CREF Investment Management LLC now owns 13,203 shares of the biopharmaceutical company’s stock worth $2,827,000 after acquiring an additional 434 shares during the period. Teachers Advisors LLC increased its position in Madrigal Pharmaceuticals by 12.3% during the third quarter. Teachers Advisors LLC now owns 13,180 shares of the biopharmaceutical company’s stock worth $2,822,000 after acquiring an additional 1,448 shares during the period. Macquarie Group Ltd. increased its position in Madrigal Pharmaceuticals by 37.4% during the third quarter. Macquarie Group Ltd. now owns 32,700 shares of the biopharmaceutical company’s stock worth $7,002,000 after acquiring an additional 8,900 shares during the period. Finally, HealthCor Management L.P. increased its position in Madrigal Pharmaceuticals by 33.2% during the third quarter. HealthCor Management L.P. now owns 262,860 shares of the biopharmaceutical company’s stock worth $56,286,000 after acquiring an additional 65,579 shares during the period. Institutional investors own 54.29% of the company’s stock.

NASDAQ MDGL opened at $114.00 on Wednesday. Madrigal Pharmaceuticals has a 52-week low of $41.00 and a 52-week high of $325.98.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.03). As a group, research analysts forecast that Madrigal Pharmaceuticals will post -2.19 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/11/21/traders-purchase-large-volume-of-call-options-on-madrigal-pharmaceuticals-mdgl.html.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.

See Also: How mutual funds make money

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.